These data indicated that in the real world, the designed multifunctional PROTAC PMIBcr/Abl‐R6 peptide should have great potency for Ph+ leukemia treatment, including various forms of imatinib resistance, even that of T315I. The gene discussed is ABL1; the disease is leukemia.